thirty percent of the placebo group , in contrast to 7.4 % of the atenolol group ( p less than 0.05 ) , had pathologically elevated ck-mb levels ( ie , greater than 3 % of total ck , a value compatible with acute myocardial infarction ) .
C0010290
ck-mb
C0155626
acute myocardial